{"entity":{"id":"nct06963905","kind":"trial","name":"Saci Nivo Rela for TNBC","aka":["SIMONE"],"tldr":"A phase 1/2 trial of nivolumab and sacituzumab govitecan in triple-negative breast cancer, run by Yale University, now recruiting.","summary":"Saci Nivo Rela for TNBC is a phase 1/2, randomised interventional study registered as NCT06963905 by Yale University, with a registry enrolment figure of 60 participants, started 2025-12-29 and due to reach its primary completion in 2030-12. Interventions recorded: Relatlimab FDC + Nivolumab; Sacituzumab Govitecan (SG); Nivolumab. Conditions listed: Metastatic Triple-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06963905","url":"https://clinicaltrials.gov/study/NCT06963905"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06963905","phase":"1/2","setting":"Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer","sponsor":"Yale University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06963905/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}